An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)

NCT01836133 · clinicaltrials.gov ↗

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG: Erlotinib 150 mg

Sponsor

Hoffmann-La Roche